xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05982795</url>
    </required_header>
    <id_info>
      <org_study_id>STUDY02001953</org_study_id>
      <nct_id>NCT05982795</nct_id>
    </id_info>
    <brief_title>Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome</brief_title>
    <official_title>Impact of Highly Effective Modulator Therapy on Sinonasal Microbial Communities, Host Mucosal Inflammatory Environment and Quality of Life in Adults With Cystic Fibrosis</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Dartmouth-Hitchcock Medical Center</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Dartmouth-Hitchcock Medical Center</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this observational study is to learn about the effects of a specific cystic&#xD;
        fibrosis therapy (Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy) on&#xD;
        chronic sinonasal disease. The main questions it aims to answer are:&#xD;
  &#xD;
          1. How does this therapy impact bacterial communities in the paranasal sinuses?&#xD;
  &#xD;
          2. How does this therapy impact inflammation in the paranasal sinuses and olfactory cleft?&#xD;
  &#xD;
          3. How does this therapy impact sense of smell and sinonasal disease burden in individuals&#xD;
             with cystic fibrosis?&#xD;
  &#xD;
          4. How does this therapy impact disease-specific and general quality of life of individuals&#xD;
             with cystic fibrosis?&#xD;
  &#xD;
        Participants will be asked to provide samples from their nose, complete testing of their&#xD;
        sense of smell, and complete surveys about their quality of life and sense of smell in this&#xD;
        study.&#xD;
  &#xD;
        Researchers will compare study results between patients who are currently undergoing Cystic&#xD;
        Fibrosis Transmembrane Conductance Regulator Modulator Therapy and patients who are not&#xD;
        currently undergoing therapy.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The goal of this study is to characterize the effects of Cystic Fibrosis Transmembrane&#xD;
        Conductance Regulator Modulator Therapy on the sinonasal microbial communities and&#xD;
        inflammatory profiles in adults with cystic fibrosis. Participants will be asked to complete&#xD;
        the below research activities on a 6-month basis over the course of two years to total 5&#xD;
        research visits (0 months, 6 months, 12 months, 18 months, 24 months).&#xD;
  &#xD;
        A mucus sample from the middle meatus will be obtained and stored at 4ºC until culture&#xD;
        analysis. Semi-quantitative bacterial cultures will be performed. Bacterial community&#xD;
        composition will be quantified using 16S rRNA variable region (V4) amplicon sequencing and&#xD;
        qPCR. Data preprocessing and taxonomic assignment will be performed using QIIME 2 (v 2023.2)&#xD;
        and the SILVA 138.1 rRNA database. Abundance data will be further processed in R (v 4.3.0)&#xD;
        using packages decontam, phyloseq, and vegan.&#xD;
  &#xD;
        Samples from the middle meatus and olfactory cleft will be analyzed to investigate the&#xD;
        inflammatory profiles of patients with cystic fibrosis. Both samples will be centrifuged at&#xD;
        4°C, 10,000 rpm for 10 minutes to extract the entire sample from the material. Samples will&#xD;
        be transferred by pipette to cryovials, flash-frozen in liquid nitrogen, and stored in a&#xD;
        -80°C environment until time of laboratory assay. The study will assess changes in immune&#xD;
        status through cytokine arrays. To assess innate immune responses, a Bioplex Pro Human&#xD;
        Inflammation Assay for 37 human cytokines (BD Biosciences) will be employed.&#xD;
  &#xD;
        The study will also investigate if alterations in nasal microbiome and inflammatory profile&#xD;
        correlate with changes in cystic fibrosis-specific quality of life (QOL) and olfaction&#xD;
        outcomes. Participants will be asked to complete olfactory function testing using the&#xD;
        Sniffin' Sticks extended test kit (MediSense, NL) and/or the University of Pennsylvania Smell&#xD;
        Identification Test (UPSIT). Additionally, participants will be asked to complete the four&#xD;
        following surveys to assess their quality of life as it relates to sinus symptom severity,&#xD;
        disease control, and sense of smell: Cystic Fibrosis Questionnaire-Revised, Sino-nasal&#xD;
        Outcome Test-22, Sinus Control Test, and Questionnaire of Olfactory Disorders.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">December 1, 2023</start_date>
    <completion_date type="Anticipated">December 1, 2026</completion_date>
    <primary_completion_date type="Anticipated">December 1, 2026</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Difference in nasal bacterial community composition between CFTR-MT cohort and Non-CFTR-MT cohort</measure>
      <time_frame>Baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
      <description>Difference in microbial communities in mucus swabs between cystic fibrosis patients on CFTR-MT and cystic fibrosis patients not on CFTR-MT.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Difference in inflammatory profiles between CFTR-MT cohort and Non-CFTR-MT cohort</measure>
      <time_frame>Baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
      <description>Difference in microbiome swab cytokine assay results between cystic fibrosis patients on CFTR-MT and cystic fibrosis patients not of CFTR-MT.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Difference in Sniffin' Sticks test scores between the CFTR-MT cohort and Non-CFTR-MT cohort</measure>
      <time_frame>Baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
      <description>Olfactory function will be tested using the Sniffin' Sticks extended test kit (MediSense, NL) using the established threshold, discrimination, and identification (TDI) scoring system. Threshold testing will be scored on a scale from 1 to 16 points. Discrimination scoring will be scored on a scale from 0-16 points. Identification will be scored on a scale from 0 to 16 points). A final Threshold, Discrimination, and Identification (TDI) score will be reported between 1-48. A higher score indicates better olfactory function, and a lower score indicates worse olfactory function.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Difference in the University of Pennsylvania Smell Identification Test scores between the CFTR-MT cohort and Non-CFTR-MT cohort</measure>
      <time_frame>Baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
      <description>Participants may be asked to complete the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is scored on a scale from 0-40, with a higher score indicating better olfaction.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Difference in Cystic Fibrosis Questionnaire-Revised survey responses between CFTR-MT cohort and Non-CFTR-MT cohort</measure>
      <time_frame>Baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
      <description>Participants will be asked to complete the validated Cystic Fibrosis Questionnaire-Revised survey. This survey evaluates CF-specific and general QOL metrics and has robust psychometric properties and consistent associations with health outcomes.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Difference in Sino-nasal Outcome Test-22 (SNOT-22) survey scores between CFTR-MT cohort and Non-CFTR-MT cohort</measure>
      <time_frame>Baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
      <description>Participants will be asked to complete the Sino-nasal Outcome Test-22 (SNOT-22) which is the most commonly used survey for evaluating outcomes in patients with CRS. This metric has been thoroughly validated, is widely employed, and is predictive of patient-perceived symptom control. The questionnaire has 5 domains with a total score ranging 0-110. A lower score indicates a lower severity of nasal disorder symptoms, and a higher score indicates a higher severity of nasal disorder symptoms.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Difference in Sinus Control Test survey scores between CFTR-MT cohort and Non-CFTR-MT cohort</measure>
      <time_frame>Baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
      <description>Participants will be asked to complete the validated Sinus Control Test - a 4-question questionnaire that assesses disease control in chronic rhinosinusitis. This survey is scored on a scale of 0-20, with a lower score indicating higher control of sinus symptoms and a higher score indicating lower control of sinus symptoms.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Difference in Questionnaire of Olfactory Disorder survey scores between CFTR-MT cohort and Non-CFTR-MT cohort</measure>
      <time_frame>Baseline, 6 months, 12 months, 18 months, 24 months</time_frame>
      <description>Participants will be asked to complete the questionnaire of olfactory disorders (QOD). This is a validated survey used to assess the impact of olfactory dysfunction on patients with sinonasal disease. There are 25 questions in three domains which give information about the degree to which patients suffer from olfactory impairment. This survey is scored on a scale from 0-57 points. A higher score indicates greater olfactory impairment.</description>
    </secondary_outcome>
    <number_of_groups>2</number_of_groups>
    <enrollment type="Anticipated">30</enrollment>
    <condition>Cystic Fibrosis</condition>
    <arm_group>
      <arm_group_label>CFTR-MT Group</arm_group_label>
      <description>The cohort of adult cystic fibrosis patients that are currently on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT) will be asked to complete the following research activities at baseline and every six months following for a two-year period.&#xD;
  Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge&#xD;
  The Sniffin' Sticks extended test kit and/or the University of Pennsylvania Smell Identification Test (UPSIT)&#xD;
  4 validated quality of life questionnaires:&#xD;
  Cystic Fibrosis Questionnaire Revised (CFQ-R)&#xD;
  Sino-Nasal Outcome Test-22 (SNOT-22)&#xD;
  Sinus Control Test (SCT)&#xD;
  Questionnaire of Olfactory Disorders</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Non-CFTR-MT Group</arm_group_label>
      <description>The cohort of adult cystic fibrosis patients that are not currently on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT) will be asked to complete the following research activities at baseline and every six months following for a two-year period.&#xD;
  Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge&#xD;
  The Sniffin' Sticks extended test kit and/or the University of Pennsylvania Smell Identification Test (UPSIT)&#xD;
  4 validated quality of life questionnaires:&#xD;
  Cystic Fibrosis Questionnaire Revised (CFQ-R)&#xD;
  Sino-Nasal Outcome Test-22 (SNOT-22)&#xD;
  Sinus Control Test (SCT)&#xD;
  Questionnaire of Olfactory Disorders</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge</intervention_name>
      <description>A CultureSwab MaxV(+) (BD, Franklin Lakes, NJ) will be placed under endoscopic visualization to the middle meatus through a sterile sheath (red rubber urinary catheter) and gently rotated 5 full turns or until the tip is saturated with mucus (no more than 20 seconds).&#xD;
  Under direct visualization, a sterile Leukosorb sponge (Leukosorb; Pall Scientific, Port Washington, NY) will be placed in the middle meatus. A piece of Leukosorb filter paper will additionally be placed in the olfactory cleft. The sponge and paper will be left for 5 minutes and will then be removed under direct visualization and collected for analysis.</description>
      <arm_group_label>CFTR-MT Group</arm_group_label>
      <arm_group_label>Non-CFTR-MT Group</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Olfactory Function Testing</intervention_name>
      <description>Olfactory function will be tested using the Sniffin' Sticks extended test kit (MediSense, NL) using the established threshold, discrimination, and identification (TDI) scoring system. Odors will be delivered using felt-tip pens (Sniffin' Sticks, MediSense, NL). The pen cap will be removed from the pen for approximately 3 seconds, and the pen's tip will be brought in front of the subject's nose and carefully moved from left to right nostril. Threshold testing will be obtained by asking the subject to identify the pen containing the odor from two pens containing only solvent. This will be conducted starting with the lowest concentration of odor and moving stepwise until patient is no longer able to identify the odor from the solvent.&#xD;
  Subjects may also be asked to complete the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT can be self-administered and uses microencapsulated odorants which are released by scratching standardized odor-impregnated test booklets.</description>
      <arm_group_label>CFTR-MT Group</arm_group_label>
      <arm_group_label>Non-CFTR-MT Group</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Survey Completion</intervention_name>
      <description>Participants will be asked to complete the validated Cystic Fibrosis Questionnaire-Revised (CFQ-R) survey. This survey evaluates Cystic Fibrosis-specific and general quality of life metrics.&#xD;
  Participants will also be asked to complete the validated Sino-nasal Outcome Test-22 (SNOT-22) which is the most commonly used survey for evaluating outcomes in patients with chronic rhinosinusitis.&#xD;
  Participants will also be asked to complete the validated Sinus Control Test (SCT) - a 4-question questionnaire that assesses disease control in chronic rhinosinusitis.&#xD;
  Participants will be asked to complete the questionnaire of olfactory disorders (QOD). This is a 25-question validated survey used to assess the impact of olfactory dysfunction on patients with sinonasal disease.</description>
      <arm_group_label>CFTR-MT Group</arm_group_label>
      <arm_group_label>Non-CFTR-MT Group</arm_group_label>
    </intervention>
    <biospec_retention>Samples With DNA</biospec_retention>
    <biospec_descr>
      <textblock>
        The biospecimens collected during this study will be endoscopically directed nasal samples&#xD;
        from the middle meatus and olfactory cleft.&#xD;
      </textblock>
    </biospec_descr>
    <eligibility>
      <study_pop>
        <textblock>
          The study population is adult, English-speaking cystic fibrosis patients being seen at the&#xD;
          New Hampshire Cystic Fibrosis Center.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Subjects between the ages of 18 years old (inclusive) and 99 years old (inclusive)&#xD;
  &#xD;
            -  English-speaking&#xD;
  &#xD;
            -  Diagnosed with CF as established by genetic testing combined with clinical assessment&#xD;
               and/or sweat chloride&#xD;
  &#xD;
            -  Patients being seen at the New Hampshire Cystic Fibrosis Center&#xD;
  &#xD;
            -  Adults able to sign informed consent&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Adults unable to consent&#xD;
  &#xD;
            -  Individuals who are not yet adults&#xD;
  &#xD;
            -  Prisoners&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>99 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Ryan E Little, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Ryan E Little, MD</last_name>
      <phone>(603) 650 8123</phone>
      <email>Ryan.E.Little@hitchcock.org</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Jessica P Fitzgerald, BA</last_name>
      <email>Jessica.P.Fitzgerald@hitchcock.org</email>
    </overall_contact_backup>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 1, 2023</study_first_submitted>
    <study_first_submitted_qc>August 1, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 9, 2023</study_first_posted>
    <last_update_submitted>August 1, 2023</last_update_submitted>
    <last_update_submitted_qc>August 1, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 9, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
      <investigator_full_name>Ryan.E.Little</investigator_full_name>
      <investigator_title>Assistant Professor of Surgery, Geisel School of Medicine</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Cystic Fibrosis</mesh_term>
      <mesh_term>Fibrosis</mesh_term>
    </condition_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05982795
  org study id: STUDY02001953
  nct id: NCT05982795
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this observational study is to learn about the effects of a specific cystic
        fibrosis therapy (Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy) on
        chronic sinonasal disease. The main questions it aims to answer are:
  
          1. How does this therapy impact bacterial communities in the paranasal sinuses?
  
          2. How does this therapy impact inflammation in the paranasal sinuses and olfactory cleft?
  
          3. How does this therapy impact sense of smell and sinonasal disease burden in individuals
             with cystic fibrosis?
  
          4. How does this therapy impact disease-specific and general quality of life of individuals
             with cystic fibrosis?
  
        Participants will be asked to provide samples from their nose, complete testing of their
        sense of smell, and complete surveys about their quality of life and sense of smell in this
        study.
  
        Researchers will compare study results between patients who are currently undergoing Cystic
        Fibrosis Transmembrane Conductance Regulator Modulator Therapy and patients who are not
        currently undergoing therapy.
  The goal of this study is to characterize the effects of Cystic Fibrosis Transmembrane
        Conductance Regulator Modulator Therapy on the sinonasal microbial communities and
        inflammatory profiles in adults with cystic fibrosis. Participants will be asked to complete
        the below research activities on a 6-month basis over the course of two years to total 5
        research visits (0 months, 6 months, 12 months, 18 months, 24 months).
  
        A mucus sample from the middle meatus will be obtained and stored at 4ºC until culture
        analysis. Semi-quantitative bacterial cultures will be performed. Bacterial community
        composition will be quantified using 16S rRNA variable region (V4) amplicon sequencing and
        qPCR. Data preprocessing and taxonomic assignment will be performed using QIIME 2 (v 2023.2)
        and the SILVA 138.1 rRNA database. Abundance data will be further processed in R (v 4.3.0)
        using packages decontam, phyloseq, and vegan.
  
        Samples from the middle meatus and olfactory cleft will be analyzed to investigate the
        inflammatory profiles of patients with cystic fibrosis. Both samples will be centrifuged at
        4°C, 10,000 rpm for 10 minutes to extract the entire sample from the material. Samples will
        be transferred by pipette to cryovials, flash-frozen in liquid nitrogen, and stored in a
        -80°C environment until time of laboratory assay. The study will assess changes in immune
        status through cytokine arrays. To assess innate immune responses, a Bioplex Pro Human
        Inflammation Assay for 37 human cytokines (BD Biosciences) will be employed.
  
        The study will also investigate if alterations in nasal microbiome and inflammatory profile
        correlate with changes in cystic fibrosis-specific quality of life (QOL) and olfaction
        outcomes. Participants will be asked to complete olfactory function testing using the
        Sniffin' Sticks extended test kit (MediSense, NL) and/or the University of Pennsylvania Smell
        Identification Test (UPSIT). Additionally, participants will be asked to complete the four
        following surveys to assess their quality of life as it relates to sinus symptom severity,
        disease control, and sense of smell: Cystic Fibrosis Questionnaire-Revised, Sino-nasal
        Outcome Test-22, Sinus Control Test, and Questionnaire of Olfactory Disorders.
  observational model: Cohort
  time perspective: Prospective
  measure: Difference in nasal bacterial community composition between CFTR-MT cohort and Non-CFTR-MT cohort
  time frame: Baseline, 6 months, 12 months, 18 months, 24 months
  description: Difference in microbial communities in mucus swabs between cystic fibrosis patients on CFTR-MT and cystic fibrosis patients not on CFTR-MT.
  measure: Difference in inflammatory profiles between CFTR-MT cohort and Non-CFTR-MT cohort
  time frame: Baseline, 6 months, 12 months, 18 months, 24 months
  description: Difference in microbiome swab cytokine assay results between cystic fibrosis patients on CFTR-MT and cystic fibrosis patients not of CFTR-MT.
  measure: Difference in Sniffin' Sticks test scores between the CFTR-MT cohort and Non-CFTR-MT cohort
  time frame: Baseline, 6 months, 12 months, 18 months, 24 months
  description: Olfactory function will be tested using the Sniffin' Sticks extended test kit (MediSense, NL) using the established threshold, discrimination, and identification (TDI) scoring system. Threshold testing will be scored on a scale from 1 to 16 points. Discrimination scoring will be scored on a scale from 0-16 points. Identification will be scored on a scale from 0 to 16 points). A final Threshold, Discrimination, and Identification (TDI) score will be reported between 1-48. A higher score indicates better olfactory function, and a lower score indicates worse olfactory function.
  measure: Difference in the University of Pennsylvania Smell Identification Test scores between the CFTR-MT cohort and Non-CFTR-MT cohort
  time frame: Baseline, 6 months, 12 months, 18 months, 24 months
  description: Participants may be asked to complete the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT is scored on a scale from 0-40, with a higher score indicating better olfaction.
  measure: Difference in Cystic Fibrosis Questionnaire-Revised survey responses between CFTR-MT cohort and Non-CFTR-MT cohort
  time frame: Baseline, 6 months, 12 months, 18 months, 24 months
  description: Participants will be asked to complete the validated Cystic Fibrosis Questionnaire-Revised survey. This survey evaluates CF-specific and general QOL metrics and has robust psychometric properties and consistent associations with health outcomes.
  measure: Difference in Sino-nasal Outcome Test-22 (SNOT-22) survey scores between CFTR-MT cohort and Non-CFTR-MT cohort
  time frame: Baseline, 6 months, 12 months, 18 months, 24 months
  description: Participants will be asked to complete the Sino-nasal Outcome Test-22 (SNOT-22) which is the most commonly used survey for evaluating outcomes in patients with CRS. This metric has been thoroughly validated, is widely employed, and is predictive of patient-perceived symptom control. The questionnaire has 5 domains with a total score ranging 0-110. A lower score indicates a lower severity of nasal disorder symptoms, and a higher score indicates a higher severity of nasal disorder symptoms.
  measure: Difference in Sinus Control Test survey scores between CFTR-MT cohort and Non-CFTR-MT cohort
  time frame: Baseline, 6 months, 12 months, 18 months, 24 months
  description: Participants will be asked to complete the validated Sinus Control Test - a 4-question questionnaire that assesses disease control in chronic rhinosinusitis. This survey is scored on a scale of 0-20, with a lower score indicating higher control of sinus symptoms and a higher score indicating lower control of sinus symptoms.
  measure: Difference in Questionnaire of Olfactory Disorder survey scores between CFTR-MT cohort and Non-CFTR-MT cohort
  time frame: Baseline, 6 months, 12 months, 18 months, 24 months
  description: Participants will be asked to complete the questionnaire of olfactory disorders (QOD). This is a validated survey used to assess the impact of olfactory dysfunction on patients with sinonasal disease. There are 25 questions in three domains which give information about the degree to which patients suffer from olfactory impairment. This survey is scored on a scale from 0-57 points. A higher score indicates greater olfactory impairment.
  arm group label: CFTR-MT Group
  description: The cohort of adult cystic fibrosis patients that are currently on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT) will be asked to complete the following research activities at baseline and every six months following for a two-year period.
  Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge
  The Sniffin' Sticks extended test kit and/or the University of Pennsylvania Smell Identification Test (UPSIT)
  4 validated quality of life questionnaires:
  Cystic Fibrosis Questionnaire Revised (CFQ-R)
  Sino-Nasal Outcome Test-22 (SNOT-22)
  Sinus Control Test (SCT)
  Questionnaire of Olfactory Disorders
  arm group label: Non-CFTR-MT Group
  description: The cohort of adult cystic fibrosis patients that are not currently on Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy (CFTR-MT) will be asked to complete the following research activities at baseline and every six months following for a two-year period.
  Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge
  The Sniffin' Sticks extended test kit and/or the University of Pennsylvania Smell Identification Test (UPSIT)
  4 validated quality of life questionnaires:
  Cystic Fibrosis Questionnaire Revised (CFQ-R)
  Sino-Nasal Outcome Test-22 (SNOT-22)
  Sinus Control Test (SCT)
  Questionnaire of Olfactory Disorders
  intervention type: Other
  intervention name: Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge
  description: A CultureSwab MaxV(+) (BD, Franklin Lakes, NJ) will be placed under endoscopic visualization to the middle meatus through a sterile sheath (red rubber urinary catheter) and gently rotated 5 full turns or until the tip is saturated with mucus (no more than 20 seconds).
  Under direct visualization, a sterile Leukosorb sponge (Leukosorb; Pall Scientific, Port Washington, NY) will be placed in the middle meatus. A piece of Leukosorb filter paper will additionally be placed in the olfactory cleft. The sponge and paper will be left for 5 minutes and will then be removed under direct visualization and collected for analysis.
  arm group label: CFTR-MT Group
  arm group label: Non-CFTR-MT Group
  intervention type: Other
  intervention name: Olfactory Function Testing
  description: Olfactory function will be tested using the Sniffin' Sticks extended test kit (MediSense, NL) using the established threshold, discrimination, and identification (TDI) scoring system. Odors will be delivered using felt-tip pens (Sniffin' Sticks, MediSense, NL). The pen cap will be removed from the pen for approximately 3 seconds, and the pen's tip will be brought in front of the subject's nose and carefully moved from left to right nostril. Threshold testing will be obtained by asking the subject to identify the pen containing the odor from two pens containing only solvent. This will be conducted starting with the lowest concentration of odor and moving stepwise until patient is no longer able to identify the odor from the solvent.
  Subjects may also be asked to complete the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT can be self-administered and uses microencapsulated odorants which are released by scratching standardized odor-impregnated test booklets.
  arm group label: CFTR-MT Group
  arm group label: Non-CFTR-MT Group
  intervention type: Other
  intervention name: Survey Completion
  description: Participants will be asked to complete the validated Cystic Fibrosis Questionnaire-Revised (CFQ-R) survey. This survey evaluates Cystic Fibrosis-specific and general quality of life metrics.
  Participants will also be asked to complete the validated Sino-nasal Outcome Test-22 (SNOT-22) which is the most commonly used survey for evaluating outcomes in patients with chronic rhinosinusitis.
  Participants will also be asked to complete the validated Sinus Control Test (SCT) - a 4-question questionnaire that assesses disease control in chronic rhinosinusitis.
  Participants will be asked to complete the questionnaire of olfactory disorders (QOD). This is a 25-question validated survey used to assess the impact of olfactory dysfunction on patients with sinonasal disease.
  arm group label: CFTR-MT Group
  arm group label: Non-CFTR-MT Group
  The biospecimens collected during this study will be endoscopically directed nasal samples
        from the middle meatus and olfactory cleft.
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 99 Years
  healthy volunteers: No
  last name: Ryan E Little, MD
  role: Principal Investigator
  affiliation: Dartmouth-Hitchcock Medical Center
  last name: Ryan E Little, MD
  phone: (603) 650 8123
  email: Ryan.E.Little@hitchcock.org
  last name: Jessica P Fitzgerald, BA
  email: Jessica.P.Fitzgerald@hitchcock.org
  responsible party type: Principal Investigator
  investigator affiliation: Dartmouth-Hitchcock Medical Center
  investigator full name: Ryan.E.Little
  investigator title: Assistant Professor of Surgery, Geisel School of Medicine
  mesh term: Cystic Fibrosis
  mesh term: Fibrosis